Answers are grounded in this paper and cite their sources.
Current medical treatments for Parkinson’s disease (PD) address symptoms but do not impact disease progression. Protein chaperones offer a promising means of restoring proteostasis in PD and other proteinopathies. ProSAAS, a neuroendocrine peptide precursor protein [1] associated with Lewy bodies [2], was recently identified as a potential biomarker in PD [3, 4]. ProSAAS harbors a central unprocessed core chaperone sequence that prevents alpha-synuclein (α-Syn) fibrillation in vitro
No takes yet. Share an insight, caveat, or question.
Shu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: